Genomelink vs Amgen
Side-by-side comparison of AI visibility scores, market position, and capabilities
DNA app store enabling users to upload Ancestry/23andMe raw data for additional trait and health insights; $3.3M revenue positioned to capture 23andMe users after its 2024 bankruptcy filing.
About
Genomelink is a San Francisco-based DNA app store and personalized genomics platform that allows users to upload raw DNA data from Ancestry, 23andMe, or other consumer DNA tests and access a marketplace of analysis apps covering ancestry, traits, health predispositions, and wellness insights. Founded in 2017 and backed by $4.5-9 million from 500 Global, Asymmetry Ventures, and 27 total investors, Genomelink generated $3.3 million in revenue in 2024 with a 22-person team, serving consumers who want more from their raw genetic data than the original testing company provides.
Amgen (AMGN) reported $33.4B revenue in FY2024, up 19% YoY (post-Horizon acquisition). Top-5 global biotech. 10+ blockbuster drugs. ~24,000 employees. HQ: Thousand Oaks, CA. Market cap ~$130B.
About
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologics and brought landmark medicines including Epogen, Neupogen, and Enbrel to market. The company reported revenues of $33.4B in FY2024, up 19% year-over-year, boosted by the transformational $28B acquisition of Horizon Therapeutics in October 2023.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.